Yolande du Toit (Yolande Du Toit)

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 3

Top Topics

Positive Breast Cancer

Sentinel Lymph Node

Locally Advanced

Epidermal Growth Factor Receptor

Top Venues

JCO oncology practice

Advances in therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Jesse A Sussell, David J Press, Svenn Alexander Kommandantvold, Eunice Kim, Yolande du Toit, Anita Fung
Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States. Advances in therapy (2023)
Letizia Polito, Jinjoo Shim, Sara Alsterlind Hurvitz, Chau T Dang, Adam Knott, Yolande du Toit, Eleonora Restuccia, Thibaut Sanglier, Sandra M Swain
Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records. JCO oncology practice (2023)
Sandra M Swain, Harrison Macharia, Javier Cortes, Chau T Dang, Luca Gianni, Sara A Hurvitz, Christian Jackisch, Andreas Schneeweiss, Dennis Slamon, Pinuccia Valagussa, Yolande du Toit, Dominik Heinzmann, Adam Knott, Chunyan Song, Patricia Cortazar
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis. Cancers 14 (20) (2022)